Actively Recruiting
Accuracy and Safety Evaluation of a New Continuous Glucose Monitoring Device in Adults with Type 1 Diabetes
Led by SiBionics, Co, Ltd · Updated on 2026-08-04
36
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the accuracy and safety of a new real-time continuous glucose monitoring CGM device in adults with type 1 diabetes. The study aims to compare glucose readings from the CGM system with reference venous plasma samples to ensure precise and safe glucose monitoring for patients. This is an interventional study sponsored by SiBionics, Co, Ltd, involving at least 36 adult participants diagnosed with type 1 diabetes. Participants will wear two CGM sensors simultaneously for a consecutive 14-day period. Interstitial glucose levels will be recorded immediately after each venous blood sample is taken for comparison. The study includes four visits to the clinical site, beginning with screening and continuing through the monitoring period. The CGM device use and related procedures are carefully monitored throughout the study. During the study, participants will undergo venous blood sampling and CGM sensor readings at scheduled visits. Researchers will assess system performance and safety over 15 days, tracking glucose data and any device-related adverse events. Participants will be evaluated through clinical visits and compliance with study procedures. The total participation duration covers the 14-day sensor wear and all associated visits, ensuring thorough safety and accuracy data collection.
CONDITIONS
Brief Title
Evaluation of the Accuracy and Safety of a Continuous Glucose Monitoring System
Research Team
X
Xiaodong Zhao
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here